TIGIT in particular has proved to be a tricky target for drug developers, and BeiGene's decision comes just a few months after MSD abandoned the development of its anti-TIGIT antibody vibostolimab ...

A Palm Beach Gardens man has teamed up with the Dana-Farber Foundation to raise funds for cancer research after losing his ...

The firm's next-generation sequencing-based test detects single nucleotide variants, insertions, and deletions in 22 genes.

Lung cancer screening with low-dose CT could have saved tens of thousands of lives—if only we'd listened to the data back in ...

Only half of study participants continued to get annual lung cancer screenings at least two years after their first.

Pembrolizumab plus concurrent chemoradiotherapy shows ongoing antitumor activity after about 5 years of follow-up in patients ...

An independent data monitoring board found that BeiGene’s ociperlimab was unlikely to significantly boost overall survival in patients with untreated NSCLC.

An exploratory analysis shows a reduction in extrathoracic metastases and prolonged time to progression or death due to any metastases with durvalumab vs placebo.

BeiGene is scrapping ociperlimab over a disappointing phase 3 outlook two years after Novartis handed back the anti-TIGIT ...

The ultimate finish line, a world without cancer. Palm Beach Gardens man teams up with the Dana Farber Foundation to raise ...

Real Housewives of Beverly Hills star Teddi Mellencamp has been bravely battling cancer for the past two-and-a-half years, ...

Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease, today announced data from a poster ...